Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Epithelial ovarian cancer (EOC) has strong hereditary influences, with 20-25% of patients carrying pathogenic variants (PVs).
• Many PVs are found in genes responsible for DNA mismatch repair (MMR) and homologous recombination (HR) pathways.
• BRCA1 and BRCA2 gene variants are significant contributors to hereditary EOC risk.

Purpose of the Study:

• To review risk assessment strategies for epithelial ovarian cancer in the context of genetic testing.
• To highlight the clinical implications of identifying homologous recombination-deficient (HRD) EOCs.
• To discuss the role of next-generation sequencing (NGS) in managing hereditary EOC.

Main Methods:

• Review of current literature on hereditary EOC and genetic testing.
• Discussion of the utility of next-generation sequencing (NGS) for multi-gene panel testing.
• Analysis of clinical implications for chemotherapy and targeted therapy selection.

Main Results:

• Pathogenic variants in MMR and HR pathway genes are prevalent in hereditary EOC.
• Identification of HR-deficient EOCs is crucial for treatment planning, including PARP inhibitor use.
• NGS enables comprehensive and timely genetic testing for multiple EOC-associated genes.

Conclusions:

• Genetic testing is essential for assessing hereditary EOC risk.
• NGS technology facilitates efficient and broad genetic profiling for EOC.
• Understanding genetic profiles guides personalized therapeutic strategies in EOC management.